Want to see ELTP full AI Analyst Report?
Top Page
Elite Pharmaceuticals
(OTC:ELTP)
Select Model
Select Model
Rating:68Neutral
Price Target:
$0.34
▼(-11.05% Downside)
Action:Reiterated
Date:08/17/26
The score is anchored by strong financial quality (high margins and very low leverage) and supportive valuation (low P/E). These positives are moderated by weak technicals (price below key moving averages with negative MACD and very low RSI) and by execution/cash-quality risks noted in the call, including revenue/margin pressure, customer concentration, and regulatory and warrant-related uncertainty.
Positive Factors
Scale and Revenue Expansion
The sharp annual expansion shows Elite is converting recent product launches into meaningful scale. A broader own-label portfolio can improve manufacturing leverage, customer reach and the foundation for sustained growth beyond a single product.
Negative Factors
Competitive Margin Pressure
The setback demonstrates the vulnerability of generic pharmaceuticals to price competition, particularly when a major franchise drives results. Continued pricing pressure could reduce the profitability and cash contribution of recently launched products.
Read all positive and negative factors
Positive Factors
Negative Factors
Scale and Revenue Expansion
The sharp annual expansion shows Elite is converting recent product launches into meaningful scale. A broader own-label portfolio can improve manufacturing leverage, customer reach and the foundation for sustained growth beyond a single product.
Read all positive factors
Elite Pharmaceuticals (ELTP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$326.91M
Dividend YieldN/A
Average Volume (3M)951.20K
Price to Earnings (P/E)6.0
Beta (1Y)1.20
Revenue Growth33.72%
EPS GrowthN/A
CountryUS
Employees65
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.05
Shares Outstanding1,077,136,500
10 Day Avg. Volume753,540
30 Day Avg. Volume951,200
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)3.93
Price to Sales (P/S)2.61
P/FCF Ratio0.02
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Elite Pharmaceuticals Business Overview & Revenue Model
Company Description
Elite Pharmaceuticals, Inc. (ELTP) is a specialized pharmaceutical company focused on the creation and manufacturing of generic medications, as well as oral, controlled-release drug formulations. Its business activities are primarily divided into ...
How the Company Makes Money
Elite Pharmaceuticals makes money primarily by selling prescription generic drug products that it develops and/or manufactures. Revenue is generally generated through: (1) product sales of Elite-owned or co-developed generic medicines distributed ...
Elite Pharmaceuticals Earnings Call Summary
Earnings Call Date:Aug 13, 2026
(Q1-2027)
| % Change Since: |
Next Earnings Date:Nov 17, 2026
Earnings Call Sentiment Positive
The call conveyed a predominantly positive operational and strategic outlook: quarterly revenues and operating profit were steady, volumes and market share increased, pipeline progress included launches, filings and BE success, cash and R&D investment improved, and management has active plans for NASDAQ uplisting and M&A. Offsetting these positives are YoY comparisons to an unusually strong prior-quarter that create headline declines, a drop in quarter-over-quarter operating cash versus that exceptional period, higher customer concentration (60% of revenues), COGS pressures from product mix (notably Naltrexone), an unresolved FDA issue for Oxy ER that risks timing, and near-term warrant-related uncertainty. On balance the company’s financial position, pipeline momentum, and strategic opportunities outweigh the noted execution and timing risks.Positive Updates
Quarterly Revenue and Operating Profit — Steady Performance
Revenue for Q1 FY2027 was $32.4 million and operating profit was $7.5 million; both metrics are in line with the prior three quarters, reflecting steady operations.
Negative Updates
Year-over-Year Comparison to an Extraordinary Quarter
Q1 FY2027 results are lower compared with June 2025, which was an exceptional quarter driven by early-stage generic Lisdex launch pricing; this creates a YoY headline decline despite the current quarter being steady and solid.
Read all updates
Q1-2027 Updates
Positive
Negative
Quarterly Revenue and Operating Profit — Steady Performance
Revenue for Q1 FY2027 was $32.4 million and operating profit was $7.5 million; both metrics are in line with the prior three quarters, reflecting steady operations.
Read all positive updates
Company Guidance
Management's guidance emphasized steady, pipeline-driven growth and near-term corporate milestones: Q1 FY2027 revenue was $32.4M with $7.5M operating profit, cash from operations $10.1M (vs. $14.8M YoY), cash of $38.9M (up from $29.8M), working capital $84.1M (down from $94.7M due to a $17M non‑cash warrant reclassification), and R&D of $2.0M (vs. $1.7M). They reiterated continued funding for product development and facility improvements, expect the anticonvulsant ANDA (brand market ~$840M) to be filed before the planned NASDAQ uplist (target ~February), are pursuing an anticoagulant (IQVIA brand sales $26B) with a 2028 commercial goal if patent issues are resolved, and noted new launches (Methadone in April, Ropinirole ER in July). Other metrics: overall volumes +14.75% (Lisdex +10%), market-share expansion +10.2%, last fiscal year revenue ~ $140–150M, warrants (expire April 2027) could raise ~ $12M if exercised (cashless exercise would issue <79M shares), and potential U.S. tariffs (possible Aug 2028/200% later) could materially favor domestic manufacturers like Elite.Elite Pharmaceuticals Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
88
Very Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Mar 2026 | Jun 2025 | Jun 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 141.01M | 148.87M | 84.04M | 56.63M | 34.16M | 32.26M |
| Gross Profit | 60.94M | 73.48M | 40.09M | 26.36M | 16.59M | 14.80M |
| EBITDA | 45.24M | 51.98M | 2.84M | 2.52M | 6.43M | 6.49M |
| Net Income | 56.67M | 44.87M | -4.31M | 20.11M | 4.41M | 8.90M |
Balance Sheet | ||||||
| Total Assets | 139.67M | 138.29M | 96.39M | 83.65M | 40.90M | 35.15M |
| Cash, Cash Equivalents and Short-Term Investments | 38.94M | 29.80B | 11.32M | 7.11M | 7.83M | 8.54M |
| Total Debt | 2.65M | 5.82M | 10.91M | 11.74M | 3.89M | 2.78M |
| Total Liabilities | 34.84M | 39.41M | 42.87M | 26.07M | 11.94M | 9.93M |
| Stockholders Equity | 104.83M | 98.88M | 53.52M | 57.58M | 28.96M | 25.22M |
Cash Flow | ||||||
| Free Cash Flow | 17.53M | 22.82B | 4.93M | -4.09M | -2.40M | 6.01M |
| Operating Cash Flow | 19.04M | 23.75B | 7.46M | -3.28M | 3.34M | 6.51M |
| Investing Cash Flow | -1.52M | -925.63M | -2.40M | -809.65K | -5.74M | -498.57K |
| Financing Cash Flow | -306.22K | -4.32B | -825.74K | 3.39M | 1.70M | -667.13K |
Elite Pharmaceuticals Technical Analysis
Negative
0.38
Price Trends
0.37
Negative
0.36
Negative
0.42
Negative
Market Momentum
-0.01
Positive
23.30
Positive
33.52
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ELTP, the sentiment is Negative. The current price of 0.38 is above the 20-day moving average (MA) of 0.36, above the 50-day MA of 0.37, and below the 200-day MA of 0.42, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 23.30 is Positive, neither overbought nor oversold. The STOCH value of 33.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ELTP.
Elite Pharmaceuticals Risk Analysis
Elite Pharmaceuticals disclosed 40 risk factors in its most recent earnings report. Elite Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Elite Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $1.81B | 132.22 | 40.13% | ― | 81.49% | ― | |
70 Outperform | $1.77B | 16.15 | 19.19% | ― | 30.90% | ― | |
68 Neutral | $326.91M | 6.00 | 62.22% | ― | 33.72% | ― | |
60 Neutral | $5.81B | 36.40 | -326.75% | ― | 9.28% | 4917.17% | |
58 Neutral | $114.32M | -10.71 | -47.10% | ― | -25.68% | -244.92% | |
53 Neutral | $542.21M | -7.06 | 243.68% | ― | 22.56% | 5.86% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
ELTP
Elite Pharmaceuticals
0.30
-0.26
-45.89%
ANIP
ANI Pharmaceuticals
78.02
-12.60
-13.90%
CPIX
Cumberland Pharmaceuticals
7.65
5.13
203.57%
AMRX
Amneal Pharmaceuticals
18.11
8.70
92.45%
AQST
Aquestive Therapeutics
4.59
0.71
18.30%
ETON
Eton Pharmaceuticals
61.48
44.93
271.48%
Elite Pharmaceuticals Corporate Events
Business Operations and StrategyFinancial Disclosures
Elite Pharmaceuticals Reports Lower Q1 2027 Revenue, Profit
Negative
Aug 13, 2026
Elite Pharmaceuticals reported that for the first quarter of fiscal 2027, ended June 30, 2026, consolidated revenue fell to $32.4 million, down 19.5% from the same period a year earlier, when it recorded the largest quarterly revenue in its histor...
Business Operations and StrategyFinancial Disclosures
Elite Pharmaceuticals to Announce Q1 2027 Results
Neutral
Aug 10, 2026
Elite Pharmaceuticals, Inc., a Northvale, N.J.-based specialty generics producer known for oral controlled-release drugs, will report financial results for the first quarter of its 2027 fiscal year, which ended June 30, 2026, on Thursday, August 1...
Business Operations and StrategyProduct-Related Announcements
Elite launches generic Requip XL Parkinson’s treatment
Positive
Aug 4, 2026
On August 4, 2026, Elite Pharmaceuticals announced the commercial launch of its generic version of Requip XL, or ropinirole extended-release tablets, in U.S. strengths ranging from 2 mg to 12 mg. The non-ergoline dopamine agonist, used to treat Pa...
Business Operations and StrategyFinancial Disclosures
Elite Pharmaceuticals Reports Strong Revenue and Profit Growth
Positive
Jun 29, 2026
For the fiscal year ended March 31, 2026, Elite Pharmaceuticals reported consolidated revenues of $148.9 million, representing a 77% increase from the prior year. Income from operations rose to $49.1 million, up about 151%, driven largely by a ful...
Business Operations and StrategyFinancial Disclosures
Elite Pharmaceuticals Schedules Fiscal 2026 Earnings Release
Neutral
Jun 23, 2026
Elite Pharmaceuticals, Inc., a specialty generics developer and manufacturer of oral controlled-release drugs, plans to release its fiscal 2026 year-end financial results on June 29, 2026, covering the period ended March 31, 2026. The company dist...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Elite Pharmaceuticals Reports Positive Anticonvulsant Bioequivalence Study
Positive
Jun 15, 2026
On June 15, 2026, Elite Pharmaceuticals reported positive results from a pivotal bioequivalence study for an undisclosed generic anticonvulsant drug. Conducted as open-label, randomized, crossover trials in healthy adults under fasting conditions,...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Elite Pharmaceuticals Files ANDA for Blockbuster Anticoagulant Generic
Positive
Jun 1, 2026
On June 1, 2026, Elite Pharmaceuticals reported that it had submitted an Abbreviated New Drug Application to the U.S. Food and Drug Administration for a generic version of an undisclosed anticoagulant drug. The branded reference medicine generated...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.